Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Jul 25

PMID 39050801

Authors

Sarah-Jane Martin

Melanie Guenette

Jiwon Oh

Affiliations

Soon will be listed here.

Abstract

B cells are critical to the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. B cell depletion using anti-CD20 monoclonal antibodies (mAbs) has proven to be an extremely successful treatment strategy, with profound suppression of both clinical and radiological evidence of focal inflammatory disease. Several anti-CD20 mAbs are now licensed for use in MS, with ublituximab being the latest to gain regulatory approval. The unique properties of each of the anti-CD20 mAb may result in nuanced differences in timing, duration and depth of B cell depletion, with the potential for such differences to have a clinical relevance to both drug efficacy and adverse effects. In this review, we summarize the design, development, and current place in MS therapy for ublituximab.

References

Hartung D . Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics. 2017; 14(4):1018-1026. PMC: 5722771. DOI: 10.1007/s13311-017-0566-3. View

Steinman L, Fox E, Hartung H, Alvarez E, Qian P, Wray S . Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022; 387(8):704-714. DOI: 10.1056/NEJMoa2201904. View

Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View

Dorcet G, Migne H, Biotti D, Bost C, Lerebours F, Ciron J . Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. J Neurol. 2022; 269(10):5443-5453. PMC: 9159933. DOI: 10.1007/s00415-022-11197-6. View

Patel A, Sul J, Gordon M, Steinklein J, Sanguinetti S, Pramanik B . Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021; 78(6):736-740. PMC: 7967248. DOI: 10.1001/jamaneurol.2021.0627. View

Gklinos P, Dobson R . Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. Pharmaceuticals (Basel). 2023; 16(5). PMC: 10223026. DOI: 10.3390/ph16050770. View

Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View

Simonsen C, Flemmen H, Broch L, Brunborg C, Berg-Hansen P, Moen S . Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Front Neurol. 2021; 12:693017. PMC: 8248666. DOI: 10.3389/fneur.2021.693017. View

Mariottini A, Muraro P, Lunemann J . Antibody-mediated cell depletion therapies in multiple sclerosis. Front Immunol. 2022; 13:953649. PMC: 9511140. DOI: 10.3389/fimmu.2022.953649. View

10.

Bar-Or A, Calabresi P, Arnold D, Arnlod D, Markowitz C, Shafer S . Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63(3):395-400. DOI: 10.1002/ana.21363. View

11.

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

12.

McKenna A, Lin G, Whittington M, Nikitin D, Herron-Smith S, Campbell J . Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value. J Manag Care Spec Pharm. 2023; 29(7):857-861. PMC: 10387920. DOI: 10.18553/jmcp.2023.29.7.857. View

13.

Kartau M, Sipila J, Auvinen E, Palomaki M, Verkkoniemi-Ahola A . Progressive Multifocal Leukoencephalopathy: Current Insights. Degener Neurol Neuromuscul Dis. 2019; 9:109-121. PMC: 6896915. DOI: 10.2147/DNND.S203405. View

14.

De Seze J, Maillart E, Gueguen A, Laplaud D, Michel L, Thouvenot E . Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023; 14:1004795. PMC: 10076836. DOI: 10.3389/fimmu.2023.1004795. View

15.

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M . Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020; 87(5):688-699. DOI: 10.1002/ana.25701. View

16.

Toorop A, Hogenboom L, Bloem K, Kocyigit M, Commandeur N, Wijnants A . Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023; 94(6):487-493. DOI: 10.1136/jnnp-2022-330793. View

17.

Lee D, Rojas O, Gommerman J . B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2020; 20(3):179-199. PMC: 7737718. DOI: 10.1038/s41573-020-00092-2. View

18.

Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen P, Kant M . Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021; 78(10):1197-1204. PMC: 8369379. DOI: 10.1001/jamaneurol.2021.2738. View

19.

van der Kolk L, Grillo-Lopez A, Baars J, Hack C, van Oers M . Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2002; 115(4):807-11. DOI: 10.1046/j.1365-2141.2001.03166.x. View

20.

Holley J, Bremer E, Kendall A, de Bruyn M, Helfrich W, Tarr J . CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Mult Scler Relat Disord. 2015; 3(5):650-8. DOI: 10.1016/j.msard.2014.06.001. View